Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Karuna Therapeutics Inc. Surges After Trial Meets Primary Endpoint

Published 08/08/2022, 19:30
Updated 08/08/2022, 19:30
© Reuters.

© Reuters.

By Sam Boughedda

Premarket Monday, Karuna Therapeutics Inc . (NASDAQ:KRTX) announced positive topline results from its Phase 3 EMERGENT-2 trial, which met its primary and key secondary endpoints.

The trial evaluated the drug's efficacy, safety, and tolerability in adults with schizophrenia, with Karuna stating it demonstrated a "statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo."

Here's how analysts reacted to the news:

A Citi analyst raised the firm's price target on the stock to $280 per share from $162, reiterating a Buy rating. Citi continues to see the EMERGENT-2 results as a "near best-case scenario" that positions KarXT to be the "go-to branded antipsychotic starting in schizophrenia and possibly beyond."

"We see a multi-billion dollar peak sales opportunity in just those two indications, and despite the move today, we think shares could continue to run over the next few weeks as buy-side starts giving the company credit for KarXT's broader potential," explained the analyst.

A Wedbush analyst maintained an Outperform rating and $178 price target on the stock, telling investors they anticipate a positive stock reaction following the data. "With the data offering validation of the mechanism and strategy, and KarXT representing a novel mechanism of action, we do think physicians will be excited to use the drug," said the analyst.

A William Blair analyst kept an Outperform rating on the stock, explaining in a research note that "efficacy was driven by statistically significant improvements in both positive and negative symptoms and we expect additional data on cognition to come later."

"Combining this efficacy profile beat with KarXT's differentiated novel cholinergic mechanism should have shares up materially today and our bull case heading into the data was a greater than $200 stock," added the analyst.

Finally, an RBC Capital Markets analyst, who has an Outperform rating and $160 price target on Karuna shares, told investors the data, at first glance, looks to have lived up to and likely exceeded high Street expectations.

"No major safety red flags from what we can tell initially from the press release and slide deck- Some GI effects and cholinergic related AEs but nothing that looks like it would derail the program; no syncope or major differences in HR/BP effects previously observed, and profile continues to look very differentiated from existing antipsychotics which we continue to believe along with strong efficacy will make KarXT a treatment of choice in schizophrenia, generating out year sales of $1.3B on our estimates," wrote the analyst.

Karuna shares surged 64% Monday, hitting an all-time high.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.